Clinical Trial Update: Comparing 3 Schedules of Alimta Plus Gemzar [Phase 2]

View source ↗

Summary

This Phase 2 trial compared three schedules of Alimta (pemetrexed) plus Gemzar (gemcitabine) in Non-Small Cell Lung Cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | Phase 2 | Status: COMPLETED